Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effect of mTOR Inhibitors in Epilepsy Treatment in Children with Tuberous Sclerosis Complex Under 2 Years of Age

21 Apr 2023

Abstract excerpt

INTRODUCTION: Mechanistic target of rapamycin (mTOR) inhibitors sirolimus and everolimus are an effective therapy for subependymal giant cell astrocytomas, cardiac rhabdomyomas, renal angiomyolipomas, and lymphangioleiomyomatosis associated with tuberous sclerosis complex (TSC). Everolimus was recently approved in the EU and the USA for the treatment of refractory focal-onset seizures. Despite frequent use of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Neurofibromatosis and Schwannoma Cases
Share to PI3K/AKT/mTOR signaling in cancer
Share to Tuberous Sclerosis Complex Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37085686
DOI: 10.1007/s40120-023-00476-7

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effect of mTOR Inhibitors in Epilepsy Treatment in Children with Tuberous Sclerosis Complex Under 2 Years of AgePMID 37085686Read ↗

Recent Advances and Challenges of mTOR Inhibitors Use in the Treatment of Patients with Tuberous Sclerosis ComplexSemantic proximity Read ↗

Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complexSemantic proximity Read ↗

mTOR Inhibitors in Tuberous Sclerosis ComplexSemantic proximity Read ↗

Effectiveness and safety of everolimus treatment in patients with tuberous sclerosis complex in real-world clinical practiceSemantic proximity Read ↗

Everolimus in infants with tuberous sclerosis complex-related West syndrome: First results from a single-center prospective observational study.Semantic proximity Read ↗

Genetic Etiologies, Diagnosis, and Treatment of Tuberous Sclerosis ComplexSemantic proximity Read ↗

Modifying genetic epilepsies – Results from studies on tuberous sclerosis complexSemantic proximity Read ↗

Therapeutic Potential of Oral Everolimus for Facial Angiofi-bromas in Pediatric Tuberous Sclerosis Complex: A Case-Based Analysis of EfficacySemantic proximity Read ↗

Genetics of tuberous sclerosis complex: implications for clinical practiceSemantic proximity Read ↗

Tuberous sclerosis complex.Semantic proximity Read ↗

mTOR inhibitors in the pharmacologic management of tuberous sclerosis complex and their potential role in other rare neurodevelopmental disordersSemantic proximity Read ↗

Management of epilepsy in tuberous sclerosis complexSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.